Company intelligence / Profile preview
MediWound
- Ownership
- Public · MDWD
- Employees
- ~111
- Development stage
- Commercial
Overview
NexoBrid has demonstrated significant reduction in surgical interventions required for burn eschar removal with proven safety and efficacy across multiple global studies. EscharEx has met primary endpoints in several Phase II trials showing rapid debridement of chronic wounds with a strong safety profile. MW005 showed complete clinical/histological clearance of BCC lesions in early trials[1][4][9].
- Therapeutic areas
- OncologyDermatology
- Modalities
- Enzymatic biologics (proteolytic enzyme-based therapeutics)Topical biological drugs
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $172.1M
- Total revenue
- $17M
- Enterprise value
- $146.3M
Beyond the preview
Go deeper on MediWound.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MediWound.